PET, PET/CT, and PET/MR Imaging Assessment of Breast Cancer

PET Clinics

Volumn 3, Issue 3, 2008, Pages 381-393

  Ahmed Shamim, Shamim ^a   Torigian, Drew A ^b   Kumar, Rakesh ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Breast cancer; Computed tomography (CT); Magnetic resonance imaging (MRI); Oncology; PET mammography; PET CT; PET MRI; Positron emission tomography (PET)

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

BREAST CANCER; BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; HUMAN; LYMPH NODE METASTASIS; MAMMOGRAPHY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POSITRON EMISSION MAMMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; WHOLE BODY PET;

EID: 67449132002     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2009.01.001     Document Type: Review

References (78)

1. Mahner S., Schirrmacher S., Brenner W., et al. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 19 7 (2008) 1249-1254
2. Tatsumi M., Cohade C., Mourtzikos K.A., et al. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 33 3 (2006) 254-262
3. Fueger B.J., Weber W.A., Quon A., et al. Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol 7 5 (2005) 369-376
4. Fletcher S.W., Black W., Harris R., et al. Report of the International Workshop on Screening for Breast Cancer. J Natl Cancer Inst 85 20 (1993) 1644-1656
5. Tabar L., Duffy S.W., and Krusemo U.B. Detection method, tumour size and node metastases in breast cancers diagnosed during a trial of breast cancer screening. Eur J Cancer Clin Oncol 23 7 (1987) 959-962
6. Kopans D.B. The positive predictive value of mammography. AJR Am J Roentgenol 158 3 (1992) 521-526
7. Bird R.E., Wallace T.W., and Yankaskas B.C. Analysis of cancers missed at screening mammography. Radiology 184 3 (1992) 613-617
8. Kerlikowske K., Grady D., Barclay J., et al. Positive predictive value of screening mammography by age and family history of breast cancer. JAMA 270 20 (1993) 2444-2450
9. Foxcroft L.M., Evans E.B., Joshua H.K., et al. Breast cancers invisible on mammography. Aust N Z J Surg 70 3 (2000) 162-167
10. Jackson V.P. The current role of ultrasonography in breast imaging. Radiol Clin North Am 33 6 (1995) 1161-1170
11. Stavros A.T., Thickman D., Rapp C.L., et al. Solid breast nodules: use of sonography to distinguish between benign and malignant lesions. Radiology 196 1 (1995) 123-134
12. Heywang S.H., Wolf A., Pruss E., et al. MR imaging of the breast with Gd-DTPA: use and limitations. Radiology 171 1 (1989) 95-103
13. Friedrich M. MRI of the breast: state of the art. Eur Radiol 8 5 (1998) 707-725
14. Avril N., Dose J., Janicke F., et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 14 6 (1996) 1848-1857
15. Crowe Jr. J.P., Adler L.P., Shenk R.R., et al. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol 1 2 (1994) 132-140
16. Scheidhauer K., Scharl A., Pietrzyk U., et al. Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med 23 6 (1996) 618-623
17. Tse N.Y., Hoh C.K., Hawkins R.A., et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 216 1 (1992) 27-34
18. Buck A., Schirrmeister H., Kuhn T., et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 29 10 (2002) 1317-1323
19. Samson D.J., Flamm C.R., Pisano E.D., et al. Should FDG PET be used to decide whether a patient with an abnormal mammogram or breast finding at physical examination should undergo biopsy?. Acad Radiol 9 7 (2002) 773-783
20. Avril N., Schelling M., Dose J., et al. Utility of PET in breast cancer. Clin Positron Imaging 2 5 (1999) 261-271
21. Crippa F., Agresti R., Seregni E., et al. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 39 1 (1998) 4-8
22. Adler L.P., Crowe J.P., al-Kaisi N.K., et al. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 187 3 (1993) 743-750
23. Avril N., Dose J., Janicke F., et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 88 17 (1996) 1204-1209
24. Wahl R.L., Siegel B.A., Coleman R.E., et al. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the Staging Breast Cancer with PET Study Group. J Clin Oncol 22 2 (2004) 277-285
25. Kumar R., Chauhan A., Zhuang H., et al. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 98 3 (2006) 267-274
26. Buck A., Wahl A., Eicher U., et al. Combined morphological and functional imaging with FDG PET-CT for restaging breast cancer: impact on patient management. J Nucl Med 44S (2003) 78P
27. Tatsumi M., Cohade C., Mourtzikos K.A., et al. Initial experience with FDG PET-CT in the evaluation of breast cancer. J Nucl Med 44S (2003) 394P
28. Czernin J. Summary of selected PET-CT abstracts from the 2003 Society of Nuclear Medicine Annual Meeting. J Nucl Med 45 (2004) 102S-103S
29. Yang S.K., Cho N., and Moon W.K. The role of PET/CT for evaluating breast cancer. Korean J Radiol 8 5 (2007) 429-437
30. Levine E.A., Freimanis R.I., Perrier N.D., et al. Positron emission mammography: initial clinical results. Ann Surg Oncol 10 1 (2003) 86-91
31. Heusner T.A., Kuemmel S., Umutlu L., et al. Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med 49 8 (2008) 1215-1222
32. Albertini J.J., Lyman G.H., Cox C., et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 276 22 (1996) 1818-1822
33. Kumar R., Jana S., Heiba S.I., et al. Retrospective analysis of sentinel node localization in multifocal, multicentric, palpable, or nonpalpable breast cancer. J Nucl Med 44 1 (2003) 7-10
34. Kumar R., Zhuang H., Schnall M., et al. FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer. Nucl Med Commun 27 3 (2006) 231-236
35. Gil-Rendo A., Zornoza G., Garcia-Velloso M.J., et al. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg 93 6 (2006) 707-712
36. Zornoza G., Garcia-Velloso M.J., Sola J., et al. 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Eur J Surg Oncol 30 1 (2004) 15-19
37. Bellon J.R., Livingston R.B., Eubank W.B., et al. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol 27 4 (2004) 407-410
38. Wang Y., Yu J., Liu J., et al. PET-CT in the diagnosis of both primary breast cancer and axillary lymph node metastasis: initial experience. Int J Radiat Oncol Biol Phys 57 2 (2003) S362-S363
39. Zhao T.T., Li J.G., and Li Y.M. [Performance of 18F-FDG PET/CT in the detection of primary breast cancer and staging of the regional lymph nodes]. Zhonghua Zhong Liu Za Zhi 29 3 (2007) 206-209 [In Chinese]
40. Groheux D., Moretti J.L., Baillet G., et al. Effect of (18)F-FDG PET/CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys 71 3 (2008) 695-704
41. Moore N.R., Dixon A.K., Wheeler T.K., et al. Axillary fibrosis or recurrent tumour: an MRI study in breast cancer. Clin Radiol 42 1 (1990) 42-46
42. Goerres G.W., Michel S.C., Fehr M.K., et al. Follow-up of women with breast cancer: comparison between MRI and FDG PET. Eur Radiol 13 7 (2003) 1635-1644
43. Moon D.H., Maddahi J., Silverman D.H., et al. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 39 3 (1998) 431-435
44. Pelosi E., Messa C., Sironi S., et al. Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging 31 7 (2004) 932-939
45. Radan L., Ben-Haim S., Bar-Shalom R., et al. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 107 11 (2006) 2545-2551
46. Piperkova E., Raphael B., Altinyay M.E., et al. Impact of PET/CT in comparison with same day contrast enhanced CT in breast cancer management. Clin Nucl Med 32 6 (2007) 429-434
47. Richie R.C., and Swanson J.O. Breast cancer: a review of the literature. J Insur Med 35 2 (2003) 85-101
48. Newman L.A., and Sabel M. Advances in breast cancer detection and management. Med Clin North Am 87 5 (2003) 997-1028
49. Kubota M., Inoue K., Koh S., et al. Role of ultrasonography in treatment selection. Breast Cancer 10 3 (2003) 188-197
50. Zimny M., and Siggelkow W. Positron emission tomography scanning in gynecologic and breast cancers. Curr Opin Obstet Gynecol 15 1 (2003) 69-75
51. Dose J., Bleckmann C., Bachmann S., et al. Comparison of fluorodeoxyglucose positron emission tomography and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients. Nucl Med Commun 23 9 (2002) 857-864
52. Kao C.H., Hsieh J.F., Tsai S.C., et al. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res 20 3B (2000) 2189-2192
53. Eubank W.B., Mankoff D.A., Vesselle H.J., et al. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics 22 1 (2002) 5-17
54. Cook G.J., Houston S., Rubens R., et al. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16 10 (1998) 3375-3379
55. Even-Sapir E., Metser U., Flusser G., et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 45 2 (2004) 272-278
56. Isasi C.R., Moadel R.M., and Blaufox M.D. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 90 2 (2005) 105-112
57. Kim T.S., Moon W.K., Lee D.S., et al. Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer. World J Surg 25 7 (2001) 829-834
58. Nakai T., Okuyama C., Kubota T., et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 32 11 (2005) 1253-1258
59. Bonadonna G., Valagussa P., Zucali R., et al. Primary chemotherapy in surgically resectable breast cancer. CA Cancer J Clin 45 4 (1995) 227-243
60. Wang H.C., and Lo S.S. Future prospects of neoadjuvant chemotherapy in treatment of primary breast cancer. Semin Surg Oncol 12 1 (1996) 59-66
61. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 47 1 (1981) 207-214
62. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 3 (2000) 205-216
63. Price P., and Jones T. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. Eur J Cancer 31A 12 (1995) 1924-1927
64. Wahl R.L., Zasadny K., Helvie M., et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 11 11 (1993) 2101-2111
65. Bassa P., Kim E.E., Inoue T., et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 37 6 (1996) 931-938
66. Schelling M., Avril N., Nahrig J., et al. Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18 8 (2000) 1689-1695
67. Rousseau C., Devillers A., Sagan C., et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 24 34 (2006) 5366-5372
68. Kumar A, Kumar R, Seenu V. Role of 18F-FDG PET-CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol in press.
69. Heywang S.H., Fenzl G., Hahn D., et al. MR imaging of the breast: comparison with mammography and ultrasound. J Comput Assist Tomogr 10 4 (1986) 615-620
70. Bluemke D.A., Gatsonis C.A., Chen M.H., et al. Magnetic resonance imaging of the breast prior to biopsy. JAMA 292 22 (2004) 2735-2742
71. Goldflam K., Hunt K.K., Gershenwald J.E., et al. Contralateral prophylactic mastectomy: predictors of significant histologic findings. Cancer 101 9 (2004) 1977-1986
72. Orel S.G., Weinstein S.P., Schnall M.D., et al. Breast MR imaging in patients with axillary node metastases and unknown primary malignancy. Radiology 212 2 (1999) 543-549
73. Gilles R., Guinebretiere J.M., Toussaint C., et al. Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology 191 3 (1994) 633-638
74. Rosen E.L., Blackwell K.L., Baker J.A., et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol 181 5 (2003) 1275-1282
75. Partridge S.C., Gibbs J.E., Lu Y., et al. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol 179 5 (2002) 1193-1199
76. Kuhl C.K., Schmutzler R.K., Leutner C.C., et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 215 1 (2000) 267-279
77. Semple S.I., Gilbert F.J., Redpath T.W., et al. The relationship between vascular and metabolic characteristics of primary breast tumours. Eur Radiol 14 11 (2004) 2038-2045
78. Brix G., Henze M., Knopp M.V., et al. Comparison of pharmacokinetic MRI and [18F] fluorodeoxyglucose PET in the diagnosis of breast cancer: initial experience. Eur Radiol 11 10 (2001) 2058-2070